Literature DB >> 11668664

The prediction of nonresponse to pharmacotherapy in panic disorder: a review.

B R Slaap1, J A den Boer.   

Abstract

Several effective pharmacotherapeutic treatments exist for panic disorder; however, not all patients respond to treatment: between 20% to 40% are non-responders. Recent studies have reported several predictors of nonresponse to pharmacotherapy. In this review two questions are addressed: is there consensus with respect to predictors of nonresponse and are there any differences between short-term and long-term predictors? In this review both short-term and long-term outcome studies are discussed. Studies were included if at least DSM-III criteria were used and baseline variables were investigated as possible predictor of response, or nonresponse, to pharmacotherapy. Of each clinical predictor, tallies were made of the particular predictors employed and of those predictors that predicted nonresponse. It appears that a long duration of illness and severe agoraphobic avoidance are robust predictors of nonresponse, particularly in long-term studies. Personality disorders, or even personality traits, are possibly the most robust predictors of nonresponse. Several factors appear to be robust predictors of nonresponse: factors that are present before treatment and exert their influence on short-term and long-term treatment outcome. Prospective studies are needed to further investigate these factors and to test whether it is viable to intervene in an attempt to increase treatment response. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11668664     DOI: 10.1002/da.1053

Source DB:  PubMed          Journal:  Depress Anxiety        ISSN: 1091-4269            Impact factor:   6.505


  13 in total

1.  Changes in Cerebral Cortex and Limbic Brain Functions after Short-Term Paroxetine Treatment in Panic Disorder: An [F]FDG-PET Pilot Study.

Authors:  Hyun-Bo Sim; Eun-Ho Kang; Bum-Hee Yu
Journal:  Psychiatry Investig       Date:  2010-08-13       Impact factor: 2.505

2.  Anxiety symptomatology: the association with distress tolerance and anxiety sensitivity.

Authors:  Meghan E Keough; Christina J Riccardi; Kiara R Timpano; Melissa A Mitchell; Norman B Schmidt
Journal:  Behav Ther       Date:  2010-06-18

Review 3.  Predictors of pharmacotherapy response in anxiety disorders.

Authors:  Damiaan Denys; Femke de Geus
Journal:  Curr Psychiatry Rep       Date:  2005-08       Impact factor: 5.285

Review 4.  Personality and anxiety disorders.

Authors:  Mina Brandes; O Joseph Bienvenu
Journal:  Curr Psychiatry Rep       Date:  2006-08       Impact factor: 5.285

5.  Aversive imagery in panic disorder: agoraphobia severity, comorbidity, and defensive physiology.

Authors:  Lisa M McTeague; Peter J Lang; Marie-Claude Laplante; Margaret M Bradley
Journal:  Biol Psychiatry       Date:  2011-05-08       Impact factor: 13.382

Review 6.  The anxiety spectrum and the reflex physiology of defense: from circumscribed fear to broad distress.

Authors:  Lisa M McTeague; Peter J Lang
Journal:  Depress Anxiety       Date:  2012-04       Impact factor: 6.505

7.  Predictors of clinical improvement in a randomized effectiveness trial for primary care patients with panic disorder.

Authors:  Denise A Chavira; Murray B Stein; Daniela Golinelli; Cathy D Sherbourne; Michelle G Craske; Greer Sullivan; Alexander Bystritsky; Peter P Roy-Byrne
Journal:  J Nerv Ment Dis       Date:  2009-10       Impact factor: 2.254

8.  Clinicians' predictions of patient response to psychotropic medications.

Authors:  Pierre Schulz; Patricia Berney
Journal:  Dialogues Clin Neurosci       Date:  2004-03       Impact factor: 5.986

9.  Pharmacological management of panic disorder.

Authors:  Carlo Marchesi
Journal:  Neuropsychiatr Dis Treat       Date:  2008-02       Impact factor: 2.570

10.  Duration of untreated illness in panic disorder: a poor outcome risk factor?

Authors:  A Carlo Altamura; Annalisa Santini; Daniele Salvadori; Emanuela Mundo
Journal:  Neuropsychiatr Dis Treat       Date:  2005-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.